Source page: McKinsey & Company
March 11, 2026
Life Sciences | Pharmaceuticals & Medical Products
The geographic distribution of clinical trial sites has become more global since 2008.
The biopharmaceutical industry is at a pivotal moment. Rapid scientific progress and intensifying competition demand a rethinking of clinical trial delivery. Among the forces reshaping the industry is the geographic distribution of clinical trials and sites, which has become more global since 2008. As the demand for personalized medicine grows, so does the need to include diverse patient populations from around the world in clinical trials.
Further, companies face rising cost pressures and greater geopolitical complexity. Achieving a future where trials enroll twice as many patients but run twice as fast, while delivering better outcomes, will require a model that blends current best practices with innovation.
To read the article, see “Achieving best-in-class clinical trial delivery: The road to 2035,” October 28, 2025.The preview updates when you finish a field or release a slider. Saving only stores this page’s widget settings and spreadsheet data in this browser and does not write back to WordPress.